Targeting HYAL2 in the lung parenchyma and vasculature may aid in the treatment of pulmonary hypertension and pulmonary fibrosis, while anti-HYAL2 therapies may be of benefit to patients with progressive kidney disease. This evidence concerns the gene HYAL2 and pulmonary fibrosis.